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The role of doctors is unarguably changing and requires a broad skill-set that is increasingly 
diverse, requiring skills that have traditionally not been integrated with the conventional 
medical curriculum. A sound clinical education is no longer sufficient to prepare doctors for 
the working environment they will face within the NHS or elsewhere. In particular, doctors 
now require a basic understanding of health economics, a need that dates back at least as 
far as the GP fund-holding days of the 1990s, through to the Clinical Commissioning Groups 
developed out of the reorganisation of the NHS in 2012 and increasingly to the decisions 
made by the National Institute for Health and Care excellence (NICE).  While some might 
argue that, with the move towards developing skills for lifelong learning within the medical 
curriculum (a development directly linked to the push towards evidence based medicine 
popularised by David Sackett et al in the early 1990s ​1​,) such ‘extra curricular’ learning can 
be undertaken voluntarily after the formal clinical education. However, with a demanding 
clinical workload and an increasing expectation of long working hours for junior doctors, it 
seems unrealistic to expect clinicians to develop such a wide skill set ‘on the job’.  
 
And without such knowledge, how can we expect doctors to manage conversations with 
patients about the availability (or often non-availability) of certain drugs or treatments within 
the NHS? In most consultations, the patient’s questions around their illness and treatment 
can usually be answered by drawing on a combination of medical training, formal guidelines 
and clinical experience- but few doctors will have received any training in health economics, 
and many junior doctors may be facing these questions for the first time, with no previous 
experience to reflect on. 
 
This is not to say that health economics doesn’t feature within medical education at all,of 
course. At the University of Sheffield I provided some teaching as part of a programme of 
short modules designed to address topics outside of the conventional medical curriculum. 
The course aimed to cover the basics of how health economics is used to make decisions 
about which drugs and treatments will be available for patients on the NHS. I was surprised 
to find that the 12 spaces on the course filled up almost instantly, with a waiting list. I hadn't 
expected there to necessarily be huge interest in this topic and I was surprised that it was so 
popular. 
 
The idea was that the sessions were based around group discussions rather than ‘chalk and 
talk’ lectures and what came across strongly was that the students clearly wanted to get a 
decent understanding of the topic and they could see how it would benefit them in the future 
as working doctors. However, as many medical schools do not routinely cover this subject in 
the curriculum, many medical students will graduate with little understanding of how NICE 
makes decisions about which drugs will be available for them to prescribe and without 
having had the chance to develop their own views about this process. Most importantly, they 
may lack the ability to talk confidently about it with patients. 
 
As doctors, they will be at the frontline when patients arrive in the consulting room having 
read or heard stories about the latest cancer drug which has been refused funding by “penny 
pinching NHS bosses ​2​”. To bring the reality of this home to students I used a video of a real 
patient from a ​BBC news story about NICE’s decision to not fund the use of the monoclonal 
antibody Avastin (bevacizumab) in advanced colorectal cancer ​3​. When presented with a 
patient whose opinion on the matter had been informed by a potentially very limited view of 
the complex process which underpins such decisions, and who asked many quite 
reasonable questions about the decision to not fund the treatment, most of the students on 
my course quickly realised that they had little idea of how the system worked, how to convey 
it in lay terms, or what their own feelings were on how such decisions are made.  
 
We spent time looking back at the history of decision making in the NHS, the shifts in drug 
therapy that have necessitated the creation of decision-making bodies such as NICE, the 
drug development process and the role of the pharmaceutical industry in both developing 
and supporting access to new treatments. 
 
Given this opportunity to learn, the students quickly developed strong feelings on the topic, 
and also a desire to be able to talk to patients about the subject in a way that was ethical 
and honest. Through a task which required them to ‘script’ responses to some of the 
questions posed by the patient in the BBC video, the students were able to use their learning 
to practice providing answers to patients’ questions in lay terminology.  
 
Our medical school has now incorporated more teaching on this subject into the curriculum, 
ensuring its graduates have had the chance to spend at least a little time considering these 
issues. These sessions are delivered by both a clinical academic and a professor of health 
economics, who together can provide both a sound understanding of the economic methods 
that underpin decisions about which treatments to provide to patients, and also the clinical 
context around the implementation of these decisions. The message for the students is 
clear: “Doctors need to understand health economics to be effective practitioners”.  
 
Our academics also run a free open online learning course on health technology 
assessment ( ​https://futurelearn.com/courses/hta ​) which gives health professionals a brief 
introduction to the methods and processes that provide a major part of the evidence base on 
which NICE bases its decision ​, and the opportunity to discuss and debate the issues with 
others. 
 
Our students, then, are fortunate to be part of a faculty that includes researchers working at 
the forefront of health economics and decision science- many other medical schools do not 
have such expertise to call on, right on their doorstep. 
 
Given the highly emotive nature of many of the media reports on drugs that aren’t offered on 
the NHS and the limited coverage about how such decisions are actually made, it is doctors 
who are best placed to provide patients with accurate information in the context of their own 
situation, and without the use of misleading statistics or complex terminology.  
 
The NHS Budget is fixed. There is not now, and may never be, enough money to provide 
every therapy, to every patient, regardless of its costs or often limited benefits.  When even 
the Cancer Drugs Fund is having to incorporate information about cost-effectiveness into its 
decisions about which drugs can be funded by this relatively modest resource, and when 
GPs are increasingly expected to make decisions about the allocation of the NHS financial 
resources, it seems logical that basic health economics should form part of the core medical 
curriculum- it is no-longer a ‘niche’ topic for those with interest in this aspect of healthcare. 
By incorporating not just teaching on this topic, but the vital opportunities to debate these 
issues, UK medical schools can help to give the next generation of doctors the ability to 
support patients with clear information about the reasons why a certain treatment may or 
may not be available to them, and to discuss these issues with them confidently and 
honestly.  
 
You can learn more about the subjects discussed in this blog post on the upcoming Health 
Technology Assessment MOOC- a free online course on the Futurelearn platform. The next course 
starts in late 2016 and you can register at futurelearn.com/courses/hta 
 
The author is the course director of an online MSc in Health Technology Assessment at the University 
of Sheffield. 
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